Product Detail

loading

Share to:
facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

Cas No. 1374635-87-6, 1,1-Dimethylethyl N-[[1-[(5-brmo-2-chloro-4-pyrimidinyl)amino]cyclohexyl]methyl]carbamate

  • 1374635-87-6

  • C16H24BrClN4O2

  • 419.74

  • 1.397±0.06

  • 99.8% (HPLC)

  • Off-white solid

  • ES-SCLC

  • Trilaciclib; Lerociclib

  • 7/23/2039 (Trilaciclib)

  • CDK4/6

  • N

  • 2022

  • ISO 9001;ISO 14001;ISO 45001; GMP

Availability:
Inquire

Cas No. 1374635-87-6, 1,1-Dimethylethyl N-[[1-[(5-brmo-2-chloro-4-pyrimidinyl)amino]cyclohexyl]methyl]carbamate

DESCRIPTION

Trilaciclib revolutionizes the landscape of oncology therapeutics by protecting and preserving patients' bone marrow during chemotherapy. Trilaciclib's unique mechanism reduces the risk of chemotherapy-induced myelosuppression, enabling patients to undergo more effective and intensive treatment regimens. By ensuring a safer and more productive treatment journey, Trilaciclib optimizes patient outcomes and strengthens your company's commitment to advancing cancer care. Embrace this game-changer and pave the way for a new era in cancer therapeutics.

ROS

Synthesis of Trilaciclib; Root of Synthesis


Reference


- CN114014864A

- US20140274896A1

- WO2018005865


Previous: 
Next: 
Cas No. 1374635-87-6